The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia

• Publication date

  2014-06-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2014.187PMID 24912431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

  2014cited by this paper
• The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology

  2013cited by this paper
• MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

  2013cited by this paper
• A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

  2013cited by this paper
• Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

  2013cited by this paper
• MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

  2013cited by this paper
• Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

  2013cited by this paper
• A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

  2013cited by this paper
• Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

  2012cited by this paper
• MYD88 L265P mutation in Waldenstrom macroglobulinemia.

  2012cited by this paper
• MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

  2012cited by this paper
• Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

  2012cited by this paper
• Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.

  2011cited by this paper
• AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome

  2011cited by this paper
• The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

  2011cited by this paper
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

  2011cited by this paper
• Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling*

  2010cited by this paper
• Inhibitor Hijacking of Akt Activation

  2009cited by this paper
• SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

  2008cited by this paper
• Targeting NF-kappaB in Waldenstrom macroglobulinemia.

  2008cited by this paper
• Regulation of CXCR4 signaling.

  2007cited by this paper
• The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

  2007cited by this paper
• WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.

  2005cited by this paper

• Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

  2026cites this paper
• Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways

  2026cites this paper
• Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis

  2025cites this paper
• Lymphoma driver mutations at the root of somatic evolution of nerve-damaging autoantibodies in myelin associated glycoprotein neuropathy.

  2025cites this paper
• Diagnosis and Management of Waldenstrom's Macroglobulinemia

  2025cites this paper
• Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia.

  2025cites this paper
• Novel Agents and Immunotherapies for Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System: Innovating for Impact in a Disease With Unmet Needs

  2025cites this paper
• Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts

  2025cites this paper
• The Direction of Modern Therapies in Waldenström Macroglobulinaemia

  2025cites this paper
• Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

  2025cites this paper
• BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.

  2025cites this paper
• Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with high-risk disease.

  2025cites this paper
• Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia

  2025cites this paper
• Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies

  2025cites this paper
• Diagnosis and Risk Stratification in Waldenström Macroglobulinemia.

  2024cites this paper
• Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma

  2024cites this paper
• Review of BCL2 inhibitors for the treatment of Waldenström’s macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma

  2024influential citation
• Gene expression profile comparison of primary and pulmonary metastatic lesions in a dog with appendicular osteosarcoma and hypertrophic osteopathy

  2024cites this paper
• ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells

  2024cites this paper
• Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies

  2024cites this paper
• The complex nature of CXCR4 mutations in WHIM syndrome

  2024cites this paper
• Optimizing BTK Inhibition in Waldenström Macroglobulinemia.

  2024cites this paper
• Transcriptomic characterization of the human segmental endotoxin challenge model

  2024cites this paper
• Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia.

  2024cites this paper
• How we use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia.

  2024cites this paper
• Immune-Related Genes and Immune Cell Infiltration Characterize the Maturation Status of Arteriovenous Fistulas: An Integrative Bioinformatics Study and Experimental Validation Based on Transcriptome Sequencing

  2024cites this paper
• Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage

  2023cites this paper
• New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia

  2023cites this paper
• Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level

  2023cites this paper
• Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.

  2023cites this paper
• Biclonal lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with POEMS syndrome: A case report and literature review

  2023cites this paper
• Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

  2022influential citation
• Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation

  2022cites this paper
• Effects of Tumor-Derived DNA on CXCL12-CXCR4 and CCL21-CCR7 Axes of Hepatocellular Carcinoma Cells and the Regulation of Sinomenine Hydrochloride

  2022cites this paper
• Monoclonal antibody-based therapies for Waldenström's macroglobulinemia

  2022cites this paper
• Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond

  2022cites this paper
• The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

  2022cites this paper
• Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance

  2022cites this paper
• Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia

  2022cites this paper
• Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia

  2022cites this paper
• First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis

  2022cites this paper
• The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.

  2022cites this paper
• Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia.

  2022cites this paper
• Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study

  2022cites this paper
• Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

  2022cites this paper
• Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies

  2022cites this paper
• Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib

  2022cites this paper
• Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response.

  2021cites this paper
• Towards precision medicine in lymphoid malignancies

  2021cites this paper
• Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective

  2021cites this paper
• Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4

  2021cites this paper
• Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy

  2021cites this paper
• Barriers to achieving a cure in lymphoma

  2021cites this paper
• The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma

  2021cites this paper
• Chemokine Receptor Antagonists: Role in Oncology

  2021cites this paper
• A review of gliomas-related proteins. Characteristics of potential biomarkers.

  2021cites this paper
• CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness

  2021cites this paper
• Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia.

  2021cites this paper
• A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

  2021cites this paper
• Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

  2021cites this paper
• Molecular processes mediating hyperhomocysteinemia-induced metabolic reprogramming, redox regulation and growth inhibition in endothelial cells

  2021cites this paper
• Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway

  2021cites this paper
• Stance of MRD in Non-Hodgkin’s Lymphoma and its upsurge in the novel era of cell-free DNA

  2021cites this paper
• Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

  2021cites this paper
• Lactoferrin is required for early B cell development in C57BL/6 mice

  2021cites this paper
• Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenström macroglobulinemia

  2021cites this paper
• Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia

  2021cites this paper
• Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune‐mediated diseases

  2021cites this paper
• Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

  2021cites this paper
• Current and novel BTK inhibitors in Waldenström’s macroglobulinemia

  2021cites this paper
• Current and Emerging Treatments for Waldenström Macroglobulinemia

  2020cites this paper
• Zanubrutinib for the treatment of Waldenström Macroglobulinemia

  2020cites this paper
• An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia

  2020cites this paper
• TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.

  2020cites this paper
• The current role of BTK inhibitors in the treatment of Waldenstrom’s Macroglobulinemia

  2020cites this paper
• CXCR4 in Waldenström’s Macroglobulinema: chances and challenges

  2020cites this paper
• Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.

  2020cites this paper
• Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies

  2020cites this paper
• At the Bench: Pre‐clinical evidence for multiple functions of CXCR4 in cancer

  2020cites this paper
• Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies

  2020cites this paper
• New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM

  2020cites this paper
• Drug Resistance in Non-Hodgkin Lymphomas

  2020cites this paper
• Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia

  2020cites this paper
• Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

  2020cites this paper
• Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia

  2020cites this paper
• CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

  2020cites this paper
• Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

  2020cites this paper
• A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.

  2020cites this paper
• Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom’s Macroglobulinemia

  2020cites this paper
• Consenso Mexicano de Mieloma Múltiple

  2020cites this paper
• The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.

  2020cites this paper
• Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

  2020cites this paper
• Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

  2020cites this paper
• Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

  2019cites this paper
• CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression

  2019cites this paper
• Resistance mechanism for ibrutinib in marginal zone lymphoma.

  2019cites this paper
• How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy

  2019cites this paper
• Cxcr4 desensitization is an essential regulatory mechanism controlling the extra-follicular B cell response

  2019cites this paper
• CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

  2019influential citation
• Current Therapeutic Options in Waldenström Macroglobulinemia

  2019cites this paper